March 2, 2026

@michaelokun

Antibody guided RNA therapy provides a precision strike against myotonic dystrophy. An antibody oligonucleotide conjugate is a therapy that uses an antibody to deliver a genetic silencing molecule directly into muscle cells to shut down harmful RNA. Nicholas Johnson and colleagues describe in a new paper in the New England Journal of Medicine how an antibody oligonucleotide conjugate called del-desiran was tested in a phase 1–2 clinical trial for myotonic dystrophy type 1. The therapy targeted the toxic genetic message that was thought to be driving the disease. Key points: – Del-desiran successfully reduced levels of toxic DMPK messenger RNA in muscle tissue by up to 46 percent, showing the therapy reached its intended target and engaged the underlying disease mechanism. – The therapy improved abnormal RNA splicing patterns in muscle, especially at higher doses, which is important because missplicing is a key driver of muscle dysfunction in myotonic dystrophy. – Most adverse events were mild to moderate, however two serious adverse events occurred, including one stroke-like event that led to treatment discontinuation and this underscores the importance of ongoing safety monitoring. My take: This study represents a major milestone. For decades, delivering RNA therapies to muscle has been a barrier. This antibody guided delivery system appears to overcome that obstacle. The signals of molecular correction and early functional improvements suggest we may be entering an era where targeted RNA therapies could alter the course of inherited neuromuscular diseases. Larger and longer trials will be essential. Here are 5 points that resonated w/ me: 1- This therapy directly targets the root genetic cause of myotonic dystrophy rather than just treating symptoms. 2- The antibody acts like a delivery vehicle that guides the therapy precisely into muscle cells. 3- Improvements in muscle biology were measurable, even in this early stage trial. 4- Safety signals require careful monitoring and remind us early phase trials are designed to learn as much as possible. 5- This approach may open the door to treating other diseases. #michaelokun #fixelinstitute